Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01862900 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01862900 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 14 participants.
The verdict
NCT01862900, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have progressive disease. The investigators hypothesize that SBRT directed at metastatic breast cancer lesions will result in a systemic anti-tumor immune system response. This amplified and directed immune response could result in anti-tumor responses.
Interventions
- BIOLOGICAL MEDI6469
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-04-27 |
| Est. Completion | 2018-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01862900
The ClinicalTrials.gov registry entry for NCT01862900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI6469 is the first listed.
NCT01862900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01862900 about?
NCT01862900 is a clinical study titled "Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions". This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have progressive disease. The investigators hypothesize that SBRT directed at m...
What is the current status of trial NCT01862900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-04-27. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT01862900?
The interventions under investigation include: MEDI6469 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01862900?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.